Patents by Inventor Dominik Escher

Dominik Escher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPLEMENT C3 ANTIGEN BINDING PROTEINS
    Publication number: 20220259296
    Abstract: Antigen-binding proteins with specificity to complement C3 and C3b are provided. Methods of treating complement C3-mediated diseases and disorders, methods of inhibiting the activity of the complement Classical pathway (CP), Lectin pathway (LP), and/or Alternative pathway (AP), and methods of inhibiting the activity of choroidal-localized complement C3 are also provided.
    Type: Application
    Filed: February 11, 2022
    Publication date: August 18, 2022
    Inventors: Leonardo BORRAS, Dominik ESCHER, Stephanie JUNGMICHEL, Christian LEISNER, Philipp Robert RICHLE, Fabian SCHEIFELE
  • Acceptor Framework for CDR Grafting
    Publication number: 20200362059
    Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Application
    Filed: May 21, 2020
    Publication date: November 19, 2020
    Inventor: Dominik Escher
  • IMMUNOGLOBULIN FRAMEWORKS WHICH DEMONSTRATE ENHANCED STABILITY IN THE INTRACELLULAR ENVIRONMENT AND METHODS OF IDENTIFYING SAME
    Publication number: 20200165322
    Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.
    Type: Application
    Filed: December 16, 2019
    Publication date: May 28, 2020
    Inventors: Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher
  • TRISPECIFIC ANTIGEN BINDING PROTEINS
    Publication number: 20200062858
    Abstract: Trispecific antigen-binding proteins including: a first binding domain capable of binding to a cell surface protein of a tumor cell; a second binding domain capable of binding to a cell surface immune checkpoint protein of the tumor cell; and a third binding domain capable of binding to a cell surface protein of an immune cell, are provided. Methods of making trispecific antigen-binding proteins are provided.
    Type: Application
    Filed: August 5, 2019
    Publication date: February 27, 2020
    Inventors: Leonardo BORRAS, Thomas SCHLEIER, Philipp Robert RICHLE, Dominik ESCHER, Christian Valdemar Vinge LEISNER, Fabian SCHEIFELE
  • Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
    Patent number: 10570190
    Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: February 25, 2020
    Assignee: Novartis AG
    Inventors: Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher
  • TRISPECIFIC ANTIGEN BINDING PROTEINS
    Publication number: 20200024358
    Abstract: Trispecific antigen-binding proteins including: a first binding domain capable of binding to a cell surface protein of a tumor cell; a second binding domain capable of binding to a cell surface immune checkpoint protein of the tumor cell; and a third binding domain capable of binding to a cell surface protein of an immune cell, are provided. Methods of making trispecific antigen-binding proteins are provided.
    Type: Application
    Filed: October 4, 2019
    Publication date: January 23, 2020
    Inventors: Leonardo BORRAS, Thomas SCHLEIER, Philipp Robert RICHLE, Dominik ESCHER, Christian Valdemar Vinge LEISNER, Fabian SCHEIFELE
  • IMMUNOGLOBULIN FRAMEWORKS WHICH DEMONSTRATE ENHANCED STABILITY IN THE INTRACELLULAR ENVIRONMENT AND METHODS OF IDENTIFYING SAME
    Publication number: 20190119361
    Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.
    Type: Application
    Filed: October 30, 2018
    Publication date: April 25, 2019
    Inventors: Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher
  • Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
    Patent number: 10125186
    Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: November 13, 2018
    Assignee: ESBATech, an Alcon Biomedical Research Unit LLC
    Inventors: Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher
  • Acceptor framework for CDR grafting
    Patent number: 9994645
    Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: June 12, 2018
    Assignee: ESBATech—a Novartis Company LLC
    Inventor: Dominik Escher
  • IMMUNOGLOBULIN FRAMEWORKS WHICH DEMONSTRATE ENHANCED STABILITY IN THE INTRACELLULAR ENVIRONMENT AND METHODS OF IDENTIFYING SAME
    Publication number: 20170107272
    Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.
    Type: Application
    Filed: November 1, 2016
    Publication date: April 20, 2017
    Inventors: Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher
  • Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
    Patent number: 9518108
    Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: December 13, 2016
    Assignee: ESBATech, an Alcon Biomedical Research Unit LLC
    Inventors: Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher
  • ACCEPTOR FRAMEWORK FOR CDR GRAFTING
    Publication number: 20160347864
    Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Application
    Filed: June 27, 2016
    Publication date: December 1, 2016
    Inventor: Dominik Escher
  • ACCEPTOR FRAMEWORK FOR CDR GRAFTING
    Publication number: 20160304627
    Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Application
    Filed: June 28, 2016
    Publication date: October 20, 2016
    Inventor: Dominik Escher
  • Acceptor framework for CDR grafting
    Patent number: 9409979
    Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: August 9, 2016
    Assignee: ESTABECH, an Alcon Biomedical Research Unit LLC
    Inventor: Dominik Escher
  • Acceptor framework for CDR grafting
    Patent number: 9403903
    Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: August 2, 2016
    Assignee: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC
    Inventor: Dominik Escher
  • ACCEPTOR FRAMEWORK FOR CDR GRAFTING
    Publication number: 20150315294
    Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Application
    Filed: May 7, 2015
    Publication date: November 5, 2015
    Inventor: Dominik Escher
  • ACCEPTOR FRAMEWORK FOR CDR GRAFTING
    Publication number: 20150232543
    Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Application
    Filed: March 11, 2015
    Publication date: August 20, 2015
    Inventor: Dominik Escher
  • Acceptor framework for CDR grafting
    Patent number: 9051366
    Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: June 9, 2015
    Inventor: Dominik Escher
  • Acceptor framework for CDR grafting
    Patent number: 9005924
    Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: April 14, 2015
    Assignee: ESBATech
    Inventor: Dominik Escher
  • IMMUNOGLOBULIN FRAMEWORKS WHICH DEMONSTRATE ENHANCED STABILITY IN THE INTRACELLULAR ENVIRONMENT AND METHODS OF IDENTIFYING SAME
    Publication number: 20150057191
    Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.
    Type: Application
    Filed: August 26, 2014
    Publication date: February 26, 2015
    Inventors: Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher